Dave Ricks, the chairman and CEO of Eli Lilly, joined widespread scientific pushback against Anthropic CEO Dario Amodei's projections. Critics emphasized that cancer encompasses numerous distinct conditions that will take more than ten years to resolve rather than the quick fixes proposed. Furthermore, specialists noted that the healthcare field simply lacks the essential data needed to support such swift developments. Commentators also voiced disappointment that major news organizations did not critically evaluate these claims leading into the public offering.
Key points
Healthcare leaders argue that Anthropic's medical projections ignore essential clinical t…: Healthcare leaders argue that Anthropic's medical projections ignore essential clinical trial constraints and critical data shortages.
The disputed claims have drawn comparisons to historical patterns of tech and medical sec…: The disputed claims have drawn comparisons to historical patterns of tech and medical sector overpromises before market debuts.
Critics expressed frustration over mainstream media outlets failing to thoroughly scrutin…: Critics expressed frustration over mainstream media outlets failing to thoroughly scrutinize Amodei's statements ahead of the public offering.
Sources checked by our analysis pipeline: 1
Moments after I posted my essay on why I couldn’t touch Anthropic’s IPO with a ten-foot pole, Anthropic’s CEO gave me (and everyone else) a reason to run away as fast as possible: a video tied to the IPO launch in which he made a bunch of overpromise about medicine that would have made Elizabeth Holmes blush.
As I have discussed before, this is not going to happen on anything remotely like that timeline. Cancer is more than one thing, and it will take more than a decade to eradicate it; the bit about curing mental illness (and some other things) that quickly is absolute fantasy.
The response from experts on X has been swift, and absolutely (and appropriately) brutal.
I was hardly the only one to get serious Elizabeth Holmes vibes. Here are four of my favorites:
§
The fact is, the field is in no position to do what Dario says, on anything like the timeline that he discusses.
On the one hand, we don’t have the data:
What Dario said about timelines just ain’t happening.
Investors are bracing for major disruptions to the chipmaker's aggressive expansion strategy following an abrupt leadership shakeup. The sudden vacancy at the top threatens to derail critical financing structures that support the company's market footprint. Consequently, institutional partners are reevaluating their commitments amid mounting uncertainty over future corporate governance.
Significant disruption now looms over major international tech initiatives due to an unexpected leadership vacancy at the chipmaking giant. The threatened capital includes both planned corporate investments and finalized agreements that were already formally executed across China's technology sector.
Emerging technology risks are drawing severe warnings directly from leadership figures within the frontier artificial intelligence sector. These internal safety concerns highlight the perceived magnitude of existential threats posed by advanced models to human survival. The stark assessment reflects ongoing debates regarding how rapidly developed autonomous systems could fundamentally endanger the public.